“Amgen seeks to monopolise an entire class of things defined by their function – every antibody that both binds to particular areas of the sweet spot of PCSK9 and blocks PCSK9 from binding to ...

anti-PCSK9 mAbs are able to bind to the catalytic domain of the PCSK9 protein, impairing its function. [Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab ...

DelveInsight's "LEQVIO Market Size, Forecast, and Market Insight Report" highlights the details around LEQVIO, which is a ...

Enzyme-linked immunosorbent assays were used to compare serum concentrations of TMAO, apolipoprotein A4 (APOA4), and proprotein convertase subtilisin/kexin type 9 (PCSK9) between patients with ...

The investigational oral PCSK9 inhibitor AZD0780 showed its LDL ... bentracimab works to get people to a normalized platelet function before surgery, SFJ and SERB Pharmaceuticals said.

James Gordon, JPMorgan: Queried the timeline for oral PCSK9 trials. EVP Ruud Dobber confirmed Phase 3 LDL-C reduction studies will begin by the end of 2025, with potential cardiovascular outcomes ...

Other CRISPR-based therapies generate a DSB at a precise location, after which cellular processes carry out the editing function ... of VERVE-101 on levels of PCSK9 and LDL cholesterol (LDC ...

This anticompetitive practice shut out an innovative therapy from the PCSK9 marketplace, not based on clinical merit or price. Because of Amgen’s size and unrelated product portfolio, their ...